Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20066061 | 0.85 | KCNH2 (0.69) | KCNH2CHRM4CHRM1CHRM2NOS2 | |
| SCHEMBL30179198 | 0.85 | KCNH2 (0.69) | KCNH2CHRM4CHRM1CHRM2NOS2 | |
| SCHEMBL30179259 | 0.80 | KCNH2 (0.52) | KCNH2CHRM4CHRM1CHRM2NOS2 | |
| SCHEMBL20066060 | 0.80 | KCNH2 (0.52) | KCNH2CHRM4CHRM1CHRM2NOS2 | |
| SCHEMBL20066057 | 0.77 | KCNH2 (0.53) | KCNH2CHRM4CHRM1CHRM2NOS2 | |
| SCHEMBL21120271 | 0.77 | CHRM4 (0.47) | KCNH2CHRM4CHRM1CHRM2NOS2 | |
| SCHEMBL30179252 | 0.77 | KCNH2 (0.53) | KCNH2CHRM4CHRM1CHRM2NOS2 | |
| SCHEMBL20066064 | 0.74 | CHRM4 (0.48) | KCNH2CHRM4CHRM1CHRM2NOS2 | |
| SCHEMBL20074536 | 0.74 | CHRM4 (0.48) | KCNH2CHRM4CHRM1CHRM2NOS2 | |
| SCHEMBL23778444 | 0.73 | KCNH2 (0.54) | KCNH2CHRM4CHRM1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526207-B1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-08 | — | — | EP | disclosed |